biotech · Hypoglycemia · Diabetes Mellitus, Type 1 · XERS
Xeris Biopharma Holdings
Xeris Biopharma Holdings clinical programs — 12 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Chicago, USA
- Founded
- 2005
- Employees
- 496
- Programs
- 16
- Drugs
- 12
- Patents
- 24
Xeris Biopharma Holdings projects
12 ClinicalTrials.gov programs sponsored by Xeris Biopharma Holdings.
Xeris Biopharma Holdings has 12 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
G-Pen Mini™ (glucagon injection)
Xeris Biopharma Holdings
Diabetes Mellitus, Type 1
2 trials -
G-Pen Mini™ (glucagon injection)
Xeris Biopharma Holdings
Hypoglycemia
1 trial -
G-Pen(TM) 1 mg
Xeris Biopharma Holdings
Hypoglycemia
1 trial -
G-Pump™ (glucagon infusion)
Xeris Biopharma Holdings
Hypoglycemia
1 trial -
Glucagon
Xeris Biopharma Holdings
Congenital Hyperinsulinism
1 trial -
Glucagon
Xeris Biopharma Holdings
Hypoglycemia
1 trial -
Glucagon RTU
Xeris Biopharma Holdings
Hyperinsulinemic Hypoglycemia
1 trial -
Glucagon RTU Injection With Insulin Pump Reduction
Xeris Biopharma Holdings
Hypoglycemia
1 trial -
Novo Nordisk GlucaGen®
Xeris Biopharma Holdings
Hypoglycemia
1 trial -
PRAM9
Xeris Biopharma Holdings
Diabetes Mellitus, Type 1
1 trial -
glucagon
Xeris Biopharma Holdings
Post-bariatric Hypoglycemia
1 trial -
levothyroxine sodium
Xeris Biopharma Holdings
Hypothyroidism
1 trial
Frequently asked questions
How many clinical projects does Xeris Biopharma Holdings have?
12 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.